Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Tick Tock ................
How about making some filters and SELLING them ???
Isn't that what a REAL business model would be ???
Asking for a friend LOL .
Yes , QUITE a while ago .. See filings : https://www.otcmarkets.com/stock/NAFS/disclosure
Agenda much ??? LOL .
$NAFS 72 mil on the bid @ 5 ... must be close now >>>
Todays "news" gives shorts the opportunity to crush .
Strange goings on today with the SP . Front loading ? MM swapping ???
Small bid-wanking ALL day , EVERY day ... 'sup ?
Turn out the lights fellas ( Like they were actually ON ) ...
02/15/2024 Expert Market SNTE Sante Technology Holdings Inc. Pink Limited Expert Market
Steady move back up ... $3.04 now >>
Canceled offering triggers short squeeze ... ( planed ? ) ..
Shorts not letting up on this .. Where to ?
$TLPH >> But , hold on ... Squeezer again perhaps ? Looks like it ... LOL .
Ya gotta wonder WHAT these guys DO all day ....?
Enjoy the weekend .. >> M
U GOTTA be F'n kidding me right now .... Bastages ! ! !
$GOGR 15 cents . Not bad ... Keep going >>>
A little " kneecapping" going on today after latest news of selling ...
10 cents is still BUPKIS to me ....
As expected , no interest in this failure .....
The ONLY successful call here is SHORT ...
When's the next R/S to keep this above $1 ... ?
Quarterly Report is out : https://www.otcmarkets.com/stock/CNHC/disclosure
Excerpt from said filing :
Note 6 – Subsequent events
On January 19, 2024, the Board of Directors of the BHPA agreed as a result of ongoing operating losses to evaluate its accounts receivable and its investment in Filecoin. As a result January 19, 2024 agreement, the Company concluded that indicators of other-than temporary impairment were present related to collection of its accounts receivable and the investment in Filecoin as of December31,2023,and upon closing. Upon analysis of the accounts receivable and its Filecoin investment, BHPA determined that other-than temporary impairment did exist and recorded a $1,930,342 ($866,065 + $1,064,277) non-cash impairment charge on January19, 2024.Theimpairments were determined based on combining the fair value of consideration received for all transactions contemplated. On January 19, 2024, Wen Jie Wu and two other related parties agreed to forgive their non interest bearing loans owed tothemof$675,002,$11,009 and $20,000, respectively. The Company’s management evaluated subsequent events through the date the financial statements were issued and there were no subsequent events to report.
Quarterly Report is out >>> https://www.otcmarkets.com/stock/BHPA/disclosure
And down we go with renewed shorting ...
$TSVT > A bit of "short covering" going on now ... How high ???
CRUSHING blow today >>> 6 cents a copy . NOT good fellas .
NOPE ... $SMURF death kneel >> Buy high , sell LOW ... Liquidation ...
12 YEARS ago today I attended GoGreen's first SHM . NOTHING since .
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=71273071
Except for incompetence and share issuance .... SAD .. ( some might say >> criminal ) .
$TLPH $ 1.17 now ...>> Upgrade >>
HC Wainwright Adjusts Talphera's Price Target to $6 From $5, Keeps Buy Rating
They will get cleared out and then we are good to GO .
Nice volume ... Let the "minnows" sell out to break even .
I am holding out for the BIG $$$ ...
0 . 0 5 9 0 1 5 C E N T S a copy for this junk ... L O L .
$CNHC >> Here we go >>> $$$
( I have NO idea what is driving this ) >> I also don't much care ... LOL >>
Expert market now > Good job fellas ... https://www.otcmarkets.com/stock/AVOZ/disclosure
S L O W "short squeeze" continues $KWE $1.46 ...
$ACRX is now $TLPH and on the move ...
( Get with the program iHub ) .
Dumpathon ? ? ?
AcelRx Announces Rebranding With Name Change to Talphera, Inc.
Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings
Talphera will begin trading on Nasdaq under the trading symbol "TLPH" effective January 10
SAN MATEO, Calif., Jan. 9, 2024 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the rebranding of the Company, with a name change to Talphera, Inc. ("Talphera"). The rebrand decision was made to reflect the Company's strategy of developing and commercializing products to support advancing care to optimize outcomes in medically supervised settings, moving beyond the original focus on acute pain. The Company's lead nafamostat product candidate, Niyad, is expected to have a Premarket Approval (PMA) submission to the FDA in the second half of 2024.
The name Talphera was derived from "Talisman", meaning a strong leader, and reflects the new "pharmaceutical era" for the Company. The company's new mission at Talphera is to support healthcare providers by developing and commercializing products in medically supervised settings that deliver advances in care to patients. Talphera will commence trading on the Nasdaq Global Market under the ticker symbol "TLPH" effective January 10, 2024.
"We were a company founded on acute pain treatments with the understanding that patient outcomes depend on the quality of the tools available to a patient's medical team. This understanding remains the focal point of our product candidates in development. Rebranding to Talphera represents a new era of the company where we have a broader mission to develop and commercialize innovative therapies for use in medically supervised settings beyond acute pain," said Vince Angotti, Chief Executive Officer of Talphera.
Talphera's lead product candidate, Niyad, has been granted FDA Breakthrough Designation and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit. If approved, Niyad would be the first-ever regional anticoagulant approved by the FDA for use in the dialysis circuit.
Talphera expects to initiate the registrational study of Niyad™, the NEPHRO CRRT (Nafamostat Efficacy in Phase 3 Registrational Continuous Renal Replacement Therapy) Study, shortly. The study has already received central Institutional Review Board (IRB) approval. The study is designed as a prospective, double-blinded trial to be conducted at up to 10 U.S. hospital intensive care units. The study will enroll and evaluate 166 adult patients undergoing renal replacement therapy, who cannot tolerate heparin or are at risk for bleeding. The primary endpoint of the study is mean post-filter activated clotting time using Niyad versus placebo over the first 24 hours. Key secondary endpoints include filter lifespan, number of filter changes over 72 hours, number of transfusions over 72 hours and dialysis efficacy (based on urea concentration) over the first 24 hours.
The first patient is expected to be enrolled for the NEPHRO study in the first quarter of 2024. Since the end of last year, the company has completed all sponsor actions and is awaiting activation from registered sites. A PMA submission for Niyad is expected to be filed with the FDA in the second half of 2024.
About Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the FDA. Talphera is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe. This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.
About Nafamostat
Nafamostat is a broad spectrum, synthetic serine protease inhibitor with anticoagulant, anti-inflammatory and potential anti-viral activities. Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation Status from the FDA. LTX-608 is a proprietary nafamostat formulation for direct IV infusion that will be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC) and acute pancreatitis.
$RGTI SP slowly creepin' up ...
Form SC 13G - Statement of acquisition of beneficial ownership by individuals
https://www.otcmarkets.com/filing/html?id=17163338&guid=cyJ-keWSJ-XCJth
$KWE New year brings new hope ? ! ? $1.22 currently ...
FAILURE : "the fact of not doing something that you must do or are expected to do."
Yup , that about sums up ANOTHER year of failure to launch ........... ANYTHING ! ! !